HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 6.06 MAC1. 27FEB25:09:36:3127FEB25:09:36:31 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS _1257722SASDATA 6.06 27FEB25:09:36:3127FEB25:09:36:31 Clnical Site Data Elements Summary HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000003800000000000000000000 STUDYID Study Identifier ÇTITLE Study Title SPONCNT Sponsor Count BEST ÕdSPONSOR Sponsor Name ÝIND IND Number BEST AUNDERINDUnder IND INDA NDA Number BEST JBLA BLA Number BEST R SUPPNUM Supplement Number BEST Z SITEID Study Site Identifier b2ARM Description of Planned Treatment Arm l2COHORT Description of Planned Cohort ž SAFPOP Number of Subjects in Safety Population BEST ÐSCREEN Number of Subjects Screened BEST ØDISCSTUDNumber Subjects Discont. Study BEST àDISCTRT Number Subjects Discont. Study TreatmentBEST èÇENDPOINTPrimary Endpoint ðENDPTYPEPrimary Endpoint Type ·TRTEFFR Treatment Efficacy Result ËTRTEFFS Treatment Efficacy Result Standard Devia ÓCENSOR Number of Censored Observations BEST ÛNSAE Number of Non-Serious Adverse Events BEST ãSAE Number of Serious Adverse Events BEST ëDEATH Number of Deaths BEST óIMPDEV Number of Important Protocol Deviations BEST ûNOIMPDEVNumber of Non-Important Protocol DeviatiBEST FINLDISCFinancial Disclosure Amount LASTNAMEInvestigator Last Name FRSTNAMEInvestigator First Name 'MINITIALInvestigator Middle Initial ;#PHONE Investigator Phone Number < FAX Investigator Fax Number _d!EMAIL Investigator Email Address x"COUNTRY Country Ü2#STATE State ß2$CITY City %POSTAL Postal Code CÇ&STREET Street Address M HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US305 Placebo B(CPBA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B(APBICð<$25,000Oppong Yaa D(b)(6) (b)(6) USANorth Carolina Fayetteville 28303 1565 Purdue Drive, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US305 mRNA-1273 B´CPA@ApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B´B]A0BóC@<$25,000Oppong Yaa D(b)(6) (b)(6) USANorth Carolina Fayetteville 28303 1565 Purdue Drive, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US305 Placebo-mRNA-1273 BCPAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?:kÝ€è?(Ê=Cî4†B‹BhABÝC?P<$25,000Oppong Yaa D(b)(6) (b)(6) USANorth Carolina Fayetteville 28303 1565 Purdue Drive, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US344 mRNA-1273 BrBöA@A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?GÜ÷}À?2]`<ÕìˆBpB™ApB1BÓ<$25,000Seger William M(b)(6) (b)(6) (b)(6) USATexas Fort Worth 76135 4504 Boat Club Road, Suite 400A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US344 Placebo BBöBA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?„!B„ ?úþ½VþøBBBB"<$25,000Seger William M(b)(6) (b)(6) (b)(6) USATexas Fort Worth 76135 4504 Boat Club Road, Suite 400A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US344 Placebo-mRNA-1273 BUBöA A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ððððððð?hˆó BPBŠA0AB6BÉ<$25,000Seger William M(b)(6) (b)(6) (b)(6) USATexas Fort Worth 76135 4504 Boat Club Road, Suite 400A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US371 mRNA-1273 B}C@A`A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?A‰7KÆ§ð?-÷þ†Ðé´B{BhA0BeCÐ<$25,000Smith William B(b)(6) (b)(6) (b)(6) USATennessee Knoxville 39720 1924 Alcoa Highway, 4 and 5 Northwest mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US371 Placebo BC@BVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?²BÈY ?®,'(šxBAÀB#B)<$25,000Smith William B(b)(6) (b)(6) (b)(6) USATennessee Knoxville 39720 1924 Alcoa Highway, 4 and 5 Northwest mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US371 Placebo-mRNA-1273 BdC@AA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ =p£× ?u8U"Ç§ôB[B™ApB‘Bí<$25,000Smith William B(b)(6) (b)(6) (b)(6) USATennessee Knoxville 39720 1924 Alcoa Highway, 4 and 5 Northwest mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US332 mRNA-1273 BÏC0AA€Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BÏBßA`BpB¤<$25,000Fragoso Veronica G(b)(6) (b)(6) (b)(6) USATexas Houston 77081 6550 Mapleridge Street, Suite 201 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US332 Placebo-mRNA-1273 B¤C0AA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÇÎ|àÇÐ?DåÑÅð BœC BVB˜<$25,000Fragoso Veronica G(b)(6) (b)(6) (b)(6) USATexas Houston 77081 6550 Mapleridge Street, Suite 201 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US332 Placebo B'C0BA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @±;±;?®Åòxu@ØB$BAAB"B-<$25,000Fragoso Veronica G(b)(6) (b)(6) (b)(6) USATexas Houston 77081 6550 Mapleridge Street, Suite 201 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US309 mRNA-1273 B”C`A€A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B”B¡A@BzC00<$25,000Ebuh Valentine M(b)(6) (b)(6) USATexas Dallas 75224 2701 S.Hampton Rd, Suite 250 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US309 Placebo-mRNA-1273 B|C`AA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ç9Îsœç8?Tä{~‡PBuB¹ApBzC+0<$25,000Ebuh Valentine M(b)(6) (b)(6) USATexas Dallas 75224 2701 S.Hampton Rd, Suite 250 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US309 Placebo BC`BA`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ö„½¡/h?ÎqMºØGpBBABB®<$25,000Ebuh Valentine M(b)(6) (b)(6) USATexas Dallas 75224 2701 S.Hampton Rd, Suite 250 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US381 mRNA-1273 BŸCÐA0A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?gE;’„?2Þ«ËúZ¼B›C`AB#B=<$25,000Wadsworth III Larkin T(b)(6) (b)(6) (b)(6) USASt. Louis Missouri 63141 711 Old Ballas Road, Suite 105 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US381 Placebo BCÐBA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @I$’I$’?ÇZ”E™6BBA0AAB<$25,000Wadsworth III Larkin T(b)(6) (b)(6) (b)(6) USASt. Louis Missouri 63141 711 Old Ballas Road, Suite 105 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US381 Placebo-mRNA-1273 B†CÐAA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @Õø[³•?hº¢1£q„ByCAPB!Bt<$25,000Wadsworth III Larkin T(b)(6) (b)(6) (b)(6) USASt. Louis Missouri 63141 711 Old Ballas Road, Suite 105 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US311 Placebo BCBA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBA A°Bl<$25,000Simmons Todd T(b)(6) (b)(6) (b)(6) USACalifornia San Diego 92120 6719 Alvarado Road, Suite 204 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US311 mRNA-1273 BãCA APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BãB»ApB6C1<$25,000Simmons Todd T(b)(6) (b)(6) (b)(6) USACalifornia San Diego 92120 6719 Alvarado Road, Suite 204 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US311 Placebo-mRNA-1273 BÍCA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ŸØ ý€ŸØ?7fQ|>`°BÅB¬A BTC00<$25,000Simmons Todd T(b)(6) (b)(6) (b)(6) USACalifornia San Diego 92120 6719 Alvarado Road, Suite 204 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US318 Placebo AÐC°AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AÐA°A BB5<$25,000Briskin Toby (b)(6) (b)(6) (b)(6) USAOhio Cleveland 44122 3619 Park East Drive, Suite 300 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US318 mRNA-1273 B²C°A A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?à\p?òNAÞýB±BGAPBNCà<$25,000Briskin Toby (b)(6) (b)(6) (b)(6) USAOhio Cleveland 44122 3619 Park East Drive, Suite 300 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US318 Placebo-mRNA-1273 B§C°AA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?õDûf´âà?K3ö±”BBnAPBSCÀ<$25,000Briskin Toby (b)(6) (b)(6) (b)(6) USAOhio Cleveland 44122 3619 Park East Drive, Suite 300 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US350 Placebo BBÚBVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBAÐBg<$25,000Campbell Thomas B(b)(6) (b)(6) (b)(6) USAColorado Aurora 80045 12401 East 17th Avenue, Leprino Building, 3rd floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US350 mRNA-1273 BlBÚA0A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BlBpABCp<$25,000Campbell Thomas B(b)(6) (b)(6) (b)(6) USAColorado Aurora 80045 12401 East 17th Avenue, Leprino Building, 3rd floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US350 Placebo-mRNA-1273 BOBÚAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?g²:T@Ïd?Hcâÿè›TBMBHA BC<$25,000Campbell Thomas B(b)(6) (b)(6) (b)(6) USAColorado Aurora 80045 12401 East 17th Avenue, Leprino Building, 3rd floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US359 mRNA-1273 B|BýApA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B|BŸAPBWB†<$25,000Poling Terry L(b)(6) (b)(6) USAKansas Wichita 67207 1709 S. Rock Rd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US359 Placebo-mRNA-1273 BkBýAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ìÜµÔï?sAüÇØBaBA BRBv<$25,000Poling Terry L(b)(6) (b)(6) USAKansas Wichita 67207 1709 S. Rock Rd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US359 Placebo BBýAÀA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ @*©ÒøêAàA°ApB'<$25,000Poling Terry L(b)(6) (b)(6) USAKansas Wichita 67207 1709 S. Rock Rd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US384 Placebo ApB>A`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ApAPApA`<$25,000Swaminathan Shobha (b)(6) (b)(6) (b)(6) USANew Jersey Newark 07103 Infectious Disease Practice, Ambulatory Care Center, 140 Bergen St., D-Level mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US384 mRNA-1273 BB>AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BB1A A€B<$25,000Swaminathan Shobha (b)(6) (b)(6) (b)(6) USANew Jersey Newark 07103 Infectious Disease Practice, Ambulatory Care Center, 140 Bergen St., D-Level mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US384 Placebo-mRNA-1273 BB>Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @$’I$’I$@ŒZ*·ÂBBTA€B6<$25,000Swaminathan Shobha (b)(6) (b)(6) (b)(6) USANew Jersey Newark 07103 Infectious Disease Practice, Ambulatory Care Center, 140 Bergen St., D-Level mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US373 Placebo B:CB7A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B:B%AB-BŠ<$25,000Overcash Jeffrey S(b)(6) (b)(6) (b)(6) USACalifornia La Mesa 91942 5565 Grossmont Center Drive, Building 2, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US373 mRNA-1273 BÇCAðA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?)*sÇe Î?öE,bÖšBÅBØA BOC0<$25,000Overcash Jeffrey S(b)(6) (b)(6) (b)(6) USACalifornia La Mesa 91942 5565 Grossmont Center Drive, Building 2, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US373 Placebo-mRNA-1273 BŽCAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Éê]¿=H?Ji|ÚÔtôB‡BÁA@B0C°<$25,000Overcash Jeffrey S(b)(6) (b)(6) (b)(6) USACalifornia La Mesa 91942 5565 Grossmont Center Drive, Building 2, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US315 Placebo B C"BA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B B+A BB#<$25,000Khetan Shishir K(b)(6) (b)(6) (b)(6) USAMaryland Rockville 20854 1201 Seven Locks Road, Suite 111 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US315 mRNA-1273 BúC"APA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BúC @A BHC<$25,000Khetan Shishir K(b)(6) (b)(6) (b)(6) USAMaryland Rockville 20854 1201 Seven Locks Road, Suite 111 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US315 Placebo-mRNA-1273 BÜC"AA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?º.‹¢èº0?9…¯¦|\BÒC`ApBABû<$25,000Khetan Shishir K(b)(6) (b)(6) (b)(6) USAMaryland Rockville 20854 1201 Seven Locks Road, Suite 111 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US355 Placebo BC ÐBA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBAÐAà<$25,000Frey Sharon E(b)(6) (b)(6) (b)(6) USAMissouri Saint Louis 63104 Center for Vaccine Development, Edward A. Doisy Research Ctr. 1100 South Grand Blvd., 1st Floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US355 mRNA-1273 BÝC ÐA0ApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BÝC A°B.BŒ<$25,000Frey Sharon E(b)(6) (b)(6) (b)(6) USAMissouri Saint Louis 63104 Center for Vaccine Development, Edward A. Doisy Research Ctr. 1100 South Grand Blvd., 1st Floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US355 Placebo-mRNA-1273 B¿C ÐA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?«iâƒYÐ?;_0@|€B·BõAàB(Bs<$25,000Frey Sharon E(b)(6) (b)(6) (b)(6) USAMissouri Saint Louis 63104 Center for Vaccine Development, Edward A. Doisy Research Ctr. 1100 South Grand Blvd., 1st Floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US338 mRNA-1273 BŒCA A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?AÔAÔ?'ÿµQxB‹BÞAB,B‚<$25,000Green Sinikka L(b)(6) (b)(6) USATexas Cedar Park 78613 1900 Cypress Creek Road, Suite 200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US338 Placebo-mRNA-1273 B}CAAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ƒn—Oà?@z™_¯ÌByBÁBC°<$25,000Green Sinikka L(b)(6) (b)(6) USATexas Cedar Park 78613 1900 Cypress Creek Road, Suite 200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US338 Placebo AÐCAAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @±;±;@ëu6:ºAÀBA°B <$25,000Green Sinikka L(b)(6) (b)(6) USATexas Cedar Park 78613 1900 Cypress Creek Road, Suite 200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US362 Placebo B%CàB#A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B%B(BBl<$25,000Doblecki-Lewis Susanne (b)(6) (b)(6) (b)(6) USAFlorida Miami 33136 1800 N.W. 10th Avenue, 1st Floor Research Unit, Eliott Bldg IDRU mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US362 mRNA-1273 BŽCàAPAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BŽBçAPAB(C<$25,000Doblecki-Lewis Susanne (b)(6) (b)(6) (b)(6) USAFlorida Miami 33136 1800 N.W. 10th Avenue, 1st Floor Research Unit, Eliott Bldg IDRU mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US362 Placebo-mRNA-1273 BhCàAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?v'bv'bx?C9žoRdBeC€AàB&BÑ<$25,000Doblecki-Lewis Susanne (b)(6) (b)(6) (b)(6) USAFlorida Miami 33136 1800 N.W. 10th Avenue, 1st Floor Research Unit, Eliott Bldg IDRU mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US328 Placebo A`BxA`AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A`A°A A <$25,000Christensen Shane G(b)(6) (b)(6) (b)(6) USAUtah Salt Lake City 84121 6360 South 3000 East, Suite 100 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US328 mRNA-1273 B9BxAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B9B1A A B\<$25,000Christensen Shane G(b)(6) (b)(6) (b)(6) USAUtah Salt Lake City 84121 6360 South 3000 East, Suite 100 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US328 Placebo-mRNA-1273 B4BxVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?NÄìNÄìP?Nœÿ"”B3B;ApBK<$25,000Christensen Shane G(b)(6) (b)(6) (b)(6) USAUtah Salt Lake City 84121 6360 South 3000 East, Suite 100 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US364 mRNA-1273 B¨CpA`AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B¨BÉA BgC <$25,000Spector Stephen A(b)(6) (b)(6) (b)(6) USACalifornia La Jolla 92037 9452 Medical Center Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US364 Placebo-mRNA-1273 B“CpAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?§/9x)È?BØSïN¡èBB¿ApB®C<$25,000Spector Stephen A(b)(6) (b)(6) (b)(6) USACalifornia La Jolla 92037 9452 Medical Center Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US364 Placebo BCpBA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÌÌÌÌÌÌÐ?ÇEì$´ˆBA°ABB)<$25,000Spector Stephen A(b)(6) (b)(6) (b)(6) USACalifornia La Jolla 92037 9452 Medical Center Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US378 mRNA-1273 B\BÃA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B\B=A@AAð<$25,000Kalams Spyros A(b)(6) (b)(6) USATennessee Nashville 37232-25821161 21st Ave. South mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US378 Placebo AðBÃAðAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @@|ë^7¢»AàA€AAÐ<$25,000Kalams Spyros A(b)(6) (b)(6) USATennessee Nashville 37232-25821161 21st Ave. South mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US378 Placebo-mRNA-1273 BKBÃVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ä±~Kå?‰•Ë·ªÌ0BDB=A0AB<$25,000Kalams Spyros A(b)(6) (b)(6) USATennessee Nashville 37232-25821161 21st Ave. South mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US361 Placebo A BSA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A A <$25,000Rupp Richard (b)(6) (b)(6) (b)(6) USATexas League City 77573 Scaly Institute for Vaccione Sciences-Clinical Trials Program, 2785 Gulf Freeway South, Suite 165 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US361 mRNA-1273 B)BSVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B)B#ApBN<$25,000Rupp Richard (b)(6) (b)(6) (b)(6) USATexas League City 77573 Scaly Institute for Vaccione Sciences-Clinical Trials Program, 2785 Gulf Freeway South, Suite 165 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US361 Placebo-mRNA-1273 B(BSVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @™™™™™š?ÂJS¯‚½`B$B#A0AÐBh<$25,000Rupp Richard (b)(6) (b)(6) (b)(6) USATexas League City 77573 Scaly Institute for Vaccione Sciences-Clinical Trials Program, 2785 Gulf Freeway South, Suite 165 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US341 mRNA-1273 B½C@APA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B½B¾BAB–C`<$25,000Powell Richard B(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45242 4260 Glendale Milford Road, Suite 201 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US341 Placebo BC@A°A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Ã0Ã0À?¾XÔ Q BAàAB!B@<$25,000Powell Richard B(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45242 4260 Glendale Milford Road, Suite 201 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US341 Placebo-mRNA-1273 B§C@AA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?õDûf´âà?K3ö±”BB¯A B¦C <$25,000Powell Richard B(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45242 4260 Glendale Milford Road, Suite 201 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US349 Placebo AðCÐAÐAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AðBA B<$25,000Novak Richard M(b)(6) (b)(6) USAIllinois Chicago 60612 835 South Wolcott Street, Room E122 m/c 735 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US349 mRNA-1273 B“CÐAPA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B“BêApBšB«<$25,000Novak Richard M(b)(6) (b)(6) USAIllinois Chicago 60612 835 South Wolcott Street, Room E122 m/c 735 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US349 Placebo-mRNA-1273 B†CÐA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?[³•Ò&4?4Y"ÇÒBƒC`APB…BŽ<$25,000Novak Richard M(b)(6) (b)(6) USAIllinois Chicago 60612 835 South Wolcott Street, Room E122 m/c 735 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US306 mRNA-1273 BœCÐA A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BœBœAÐB!Bq<$25,000Glover, II Richard M(b)(6) (b)(6) (b)(6) USAKansas Newton 67114 700 Medical Center Drive, Suite 110 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US306 Placebo-mRNA-1273 B”CÐAAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÁºÏ‘L°?GxiPY 4BB½ApB0B÷<$25,000Glover, II Richard M(b)(6) (b)(6) (b)(6) USAKansas Newton 67114 700 Medical Center Drive, Suite 110 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US306 Placebo A`CÐA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @*ªªªªªª@&òü a&TAPA@ApAà<$25,000Glover, II Richard M(b)(6) (b)(6) (b)(6) USAKansas Newton 67114 700 Medical Center Drive, Suite 110 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US314 mRNA-1273 B‡CPA@A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B‡B'A B³C*€<$25,000Hollister Ripley R(b)(6) (b)(6) (b)(6) USAColorado Colorado Springs 80918 2855 Dublin Blvd mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US314 Placebo-mRNA-1273 ByCPA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ìõkæœ?\†ÈTÓ.ŒBqB-A0BÅC1@<$25,000Hollister Ripley R(b)(6) (b)(6) (b)(6) USAColorado Colorado Springs 80918 2855 Dublin Blvd mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US314 Placebo AÐCPA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @±;±;@ëu6:ºAÀA0ABB[<$25,000Hollister Ripley R(b)(6) (b)(6) (b)(6) USAColorado Colorado Springs 80918 2855 Dublin Blvd mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US394 Placebo BB A€APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BAPAAB+<$25,000Toma Ramy J(b)(6) (b)(6) (b)(6) USAAlabama Birmingham 35211 832 Princeton Avenue SW mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US394 Placebo-mRNA-1273 B:B A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B:BRA@BBÙ<$25,000Toma Ramy J(b)(6) (b)(6) (b)(6) USAAlabama Birmingham 35211 832 Princeton Avenue SW mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US394 mRNA-1273 BIB APA`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BIBvAPB&Bô<$25,000Toma Ramy J(b)(6) (b)(6) (b)(6) USAAlabama Birmingham 35211 832 Princeton Avenue SW mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US323 Placebo ApB·ApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ApA@AApA <$25,000Rouhbakhsh Rambod (b)(6) (b)(6) (b)(6) USAMississippi Petal 39465 206 Old Cornith Road mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US323 mRNA-1273 BWB·AA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BWB¤A0B)B¡<$25,000Rouhbakhsh Rambod (b)(6) (b)(6) (b)(6) USAMississippi Petal 39465 206 Old Cornith Road mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US323 Placebo-mRNA-1273 BOB·Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @3Ù* h?p5µà(TBJBÅA@B+B<$25,000Rouhbakhsh Rambod (b)(6) (b)(6) (b)(6) USAMississippi Petal 39465 206 Old Cornith Road mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US334 mRNA-1273 BªC BAàVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BªBæA0B0BÖ<$25,000Pickrell Paul (b)(6) (b)(6) (b)(6) USATexas Austin 78745 4534 West Gate Blvd, Suite 110 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US334 Placebo-mRNA-1273 B‰C AA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÑHà;ËÈ?M|¿B‚BéApB3Bâ<$25,000Pickrell Paul (b)(6) (b)(6) (b)(6) USATexas Austin 78745 4534 West Gate Blvd, Suite 110 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US334 Placebo B$C BA€Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ãŽ8ãŽ8à?œ_bž8/¨B"BAAB'BB<$25,000Pickrell Paul (b)(6) (b)(6) (b)(6) USATexas Austin 78745 4534 West Gate Blvd, Suite 110 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US395 mRNA-1273 BZBÞAPAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BZBEA@BBª<$25,000Jackson Booth Peta-Gay (b)(6) (b)(6) (b)(6) USAMaryland Rockville 20850 15201 Shady Grove Road, Suite 202 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US395 Placebo-mRNA-1273 BMBÞAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?51ÞÀÔÇ|?4Ù'Fzt¸BLBMA BB×<$25,000Jackson Booth Peta-Gay (b)(6) (b)(6) (b)(6) USAMaryland Rockville 20850 15201 Shady Grove Road, Suite 202 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US395 Placebo AðBÞAAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @@|ë^7¢»AàAÐA0ABB4<$25,000Jackson Booth Peta-Gay (b)(6) (b)(6) (b)(6) USAMaryland Rockville 20850 15201 Shady Grove Road, Suite 202 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US302 Placebo AðCðA°A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AðAàA A B#<$25,000Bradley Paul S(b)(6) (b)(6) (b)(6) USAGeorgia Savannah 31406 340 Eisenhower Drive, Suite 1200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US302 mRNA-1273 B’CðA@A`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Àà?õcŸsŽB‘BŽAÀB8C<$25,000Bradley Paul S(b)(6) (b)(6) (b)(6) USAGeorgia Savannah 31406 340 Eisenhower Drive, Suite 1200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US302 Placebo-mRNA-1273 B„CðVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?]EÑt]?5!½®@bœBBnApBUC<$25,000Bradley Paul S(b)(6) (b)(6) (b)(6) USAGeorgia Savannah 31406 340 Eisenhower Drive, Suite 1200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US396 Placebo A`BvA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A`A@AAP<$25,000Nugent Paul J(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45236 8250 Kenwood Crossing Way, Suite 100 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US396 mRNA-1273 B0BvAAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B0BEA0AA€BC<$25,000Nugent Paul J(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45236 8250 Kenwood Crossing Way, Suite 100 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US396 Placebo-mRNA-1273 B,BvAAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @"èº.‹¢è?Óè’Ì-F¸B&BCA B2<$25,000Nugent Paul J(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45236 8250 Kenwood Crossing Way, Suite 100 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US348 mRNA-1273 B•CpA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?RxD¹Žš ?/!×R¬PB’B½ABC@<$25,000Rouphael Nadine (b)(6) (b)(6) USAGeorgia Decatur 30030 500 Irvin Court, Suite 200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US348 Placebo-mRNA-1273 BŠCpAA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?”gâQŸ‰H?A'ÙBñHB…BÆA B!C<$25,000Rouphael Nadine (b)(6) (b)(6) USAGeorgia Decatur 30030 500 Irvin Court, Suite 200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US348 Placebo A€CpAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ @îêh?IApA A€A <$25,000Rouphael Nadine (b)(6) (b)(6) USAGeorgia Decatur 30030 500 Irvin Court, Suite 200 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US393 mRNA-1273 B‚C A ApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?øø ?bâéï±¢BB®ApA BeC,p<$25,000Sheth Neil P(b)(6) (b)(6) (b)(6) USAArizona Glendale 85306 5750 W Thunderbird Rd, Suite G790 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US393 Placebo-mRNA-1273 BiC A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ê ê è?\È~£ ˆBcB«ABRC% <$25,000Sheth Neil P(b)(6) (b)(6) (b)(6) USAArizona Glendale 85306 5750 W Thunderbird Rd, Suite G790 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US393 Placebo BC AÀAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ö„½¡/h?ÎqMºØGpBB&AàABBê<$25,000Sheth Neil P(b)(6) (b)(6) (b)(6) USAArizona Glendale 85306 5750 W Thunderbird Rd, Suite G790 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US352 mRNA-1273 CC,àA@APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event CC# AÀBqC.€<$25,000Zervos Marcus (b)(6) (b)(6) (b)(6) USAMichigan Detroit 48202 2799 W. Grand Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US352 Placebo-mRNA-1273 BíC,àA APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?E!|8+4ì?"EÀ}ÎV’BéC AÀBTC#ð<$25,000Zervos Marcus (b)(6) (b)(6) (b)(6) USAMichigan Detroit 48202 2799 W. Grand Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US352 Placebo BtC,àBtA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Fžå„iîX?1Û´HBrBQA@B7BÙ<$25,000Zervos Marcus (b)(6) (b)(6) (b)(6) USAMichigan Detroit 48202 2799 W. Grand Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US320 mRNA-1273 BÄC@AðAðVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BÄBžA ABŠC>ð<$25,000McKenzie Mark M(b)(6) (b)(6) (b)(6) USATennessee Chattanooga 37421 6035 Shallowford Road, Suite 109 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US320 Placebo-mRNA-1273 BžC@AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @3Ù* h?OW¥¢·B”BÌAðB¥C5à<$25,000McKenzie Mark M(b)(6) (b)(6) (b)(6) USATennessee Chattanooga 37421 6035 Shallowford Road, Suite 109 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US320 Placebo B'C@BA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @±;±;?®Åòxu@ØB$BAB@BÎ<$25,000McKenzie Mark M(b)(6) (b)(6) (b)(6) USATennessee Chattanooga 37421 6035 Shallowford Road, Suite 109 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US387 mRNA-1273 BôC A€B#Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÉqO¼Ú;?À ™ËëgBóC$àA A BºC5<$25,000Levin Michael L(b)(6) (b)(6) (b)(6) USANevada Las Vegas 89104 1022 East Sahara Ave mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US387 Placebo-mRNA-1273 BÝC ABVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?”E€”E€˜?3vÞg‡$PBÕC PABC-P<$25,000Levin Michael L(b)(6) (b)(6) (b)(6) USANevada Las Vegas 89104 1022 East Sahara Ave mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US387 Placebo BC BA€Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?‰Ø‰Ø ?šzªôktXBBHA B-B[<$25,000Levin Michael L(b)(6) (b)(6) (b)(6) USANevada Las Vegas 89104 1022 East Sahara Ave mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US317 mRNA-1273 BàC@BB)Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BàBRA BC<`<$25,000Kutner Mark E(b)(6) (b)(6) (b)(6) USAFlorida Miami 33135 2128 West Flagler Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US317 Placebo BiC@B'B+Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?NàNàP?6£Î 4Î BgB-A`B]C! <$25,000Kutner Mark E(b)(6) (b)(6) (b)(6) USAFlorida Miami 33135 2128 West Flagler Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US317 Placebo-mRNA-1273 BwC@A°Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?gB°gB°h?:Üw¾ð›RBtBWBBQC <$25,000Kutner Mark E(b)(6) (b)(6) (b)(6) USAFlorida Miami 33135 2128 West Flagler Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US351 Placebo BC`BAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BA`B+B<$25,000Koren Michael J(b)(6) (b)(6) (b)(6) USAFlorida Jacksonville 32216 4085 University Boulevard South, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US351 mRNA-1273 B˜C`A`APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B˜CA0AB;Bï<$25,000Koren Michael J(b)(6) (b)(6) (b)(6) USAFlorida Jacksonville 32216 4085 University Boulevard South, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US351 Placebo-mRNA-1273 BC`A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?`Áƒ0?72Äç—¬B|C A0BB¿<$25,000Koren Michael J(b)(6) (b)(6) (b)(6) USAFlorida Jacksonville 32216 4085 University Boulevard South, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US390 Placebo BB‹A€AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BAPBB6<$25,000Kimmel Murray A(b)(6) (b)(6) (b)(6) USAFlorida Melbourne 32934 3030 Venture Lane, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US390 mRNA-1273 B<B‹A0AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B<B2A@BBÊ<$25,000Kimmel Murray A(b)(6) (b)(6) (b)(6) USAFlorida Melbourne 32934 3030 Venture Lane, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US390 Placebo-mRNA-1273 B+B‹A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¾‚úè/ ?ƒŠ»ˆB)B%BBˆ<$25,000Kimmel Murray A(b)(6) (b)(6) (b)(6) USAFlorida Melbourne 32934 3030 Venture Lane, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US392 mRNA-1273 BJB³A@A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BJB[A@B#Be<$25,000Reynolds Michele D(b)(6) (b)(6) (b)(6) USATexas Dallas 75234 9 Medical Parkway, Plaza 4, Suite 202 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US392 Placebo-mRNA-1273 B?B³A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?‚ ‚ €?ZyŸµ!“„B=B]AB"B‹<$25,000Reynolds Michele D(b)(6) (b)(6) (b)(6) USATexas Dallas 75234 9 Medical Parkway, Plaza 4, Suite 202 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US392 Placebo A°B³APA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @.‹¢èº.Œ@ÅDA”¢ãAA°AÀB<$25,000Reynolds Michele D(b)(6) (b)(6) (b)(6) USATexas Dallas 75234 9 Medical Parkway, Plaza 4, Suite 202 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US339 Placebo BCPBAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BABBN<$25,000Cotugno Michael J(b)(6) (b)(6) (b)(6) USALouisiana Metairie 70006 4517 Veterans Memorial Blvd mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US339 mRNA-1273 B®CPAPA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ŠLx¤È?xôú£`BBDA`BIC0<$25,000Cotugno Michael J(b)(6) (b)(6) (b)(6) USALouisiana Metairie 70006 4517 Veterans Memorial Blvd mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US339 Placebo-mRNA-1273 B™CPA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?…Û0…Û0ˆ?:àDÇWœ¢B”B:A@BGC <$25,000Cotugno Michael J(b)(6) (b)(6) (b)(6) USALouisiana Metairie 70006 4517 Veterans Memorial Blvd mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US388 Placebo ApBIApA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ApAPAA`B*<$25,000Lewis Michael (b)(6) (b)(6) (b)(6) USACalifornia Los Angeles 90073 11301 Wilshire Blvd., Building 500, Room 1256 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US388 Placebo-mRNA-1273 BBIVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBBB‡<$25,000Lewis Michael (b)(6) (b)(6) (b)(6) USACalifornia Los Angeles 90073 11301 Wilshire Blvd., Building 500, Room 1256 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US388 mRNA-1273 BBIA AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BB!ABB˜<$25,000Lewis Michael (b)(6) (b)(6) (b)(6) USACalifornia Los Angeles 90073 11301 Wilshire Blvd., Building 500, Room 1256 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US389 Placebo ABTAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AA<$25,000Adams Michael R(b)(6) (b)(6) (b)(6) USAUtah Murray 84123 5251 South Green Street, Suite 300 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US389 mRNA-1273 B&BTA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?kÊò†¼ ?j\š²—ÀœB%B=A@AB#<$25,000Adams Michael R(b)(6) (b)(6) (b)(6) USAUtah Murray 84123 5251 South Green Street, Suite 300 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US389 Placebo-mRNA-1273 B$BTVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?qÇqÇp?p/¸zHB#B:AApB<$25,000Adams Michael R(b)(6) (b)(6) (b)(6) USAUtah Murray 84123 5251 South Green Street, Suite 300 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US391 Placebo AðBòAÐA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AðB"A AB(<$25,000Hutchens Mark H(b)(6) (b)(6) USATexas Austin 78705 3200 Red River St., Suite 301 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US391 mRNA-1273 B`BòAPAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B`B–AABC <$25,000Hutchens Mark H(b)(6) (b)(6) USATexas Austin 78705 3200 Red River St., Suite 301 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US391 Placebo-mRNA-1273 BQBòAA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?2‘aùÓÀ?2A9Šù4BPB•APB#B×<$25,000Hutchens Mark H(b)(6) (b)(6) USATexas Austin 78705 3200 Red River St., Suite 301 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US312 mRNA-1273 BEB—A@A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BEBfA BtB½<$25,000Hong Matthew H(b)(6) (b)(6) (b)(6) USANorth Carolina Raleigh 27612 3100 Duraleigh Road, Suite 303 &304 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US312 Placebo-mRNA-1273 B9B—AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¸#îû€?cÓyÒvöÐB7BAA0B^B<$25,000Hong Matthew H(b)(6) (b)(6) (b)(6) USANorth Carolina Raleigh 27612 3100 Duraleigh Road, Suite 303 &304 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US312 Placebo A°B—A A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @EÑt]F@0Ž‡)-+A A0BB <$25,000Hong Matthew H(b)(6) (b)(6) (b)(6) USANorth Carolina Raleigh 27612 3100 Duraleigh Road, Suite 303 &304 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US357 mRNA-1273 BÂC`A°AàVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?êâø?¢¦BÁCPA0ABqC@<$25,000Haber Milton (b)(6) (b)(6) USATexas Laredo 78041 2344 Laguna Del Mar Court, Suite 104 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US357 Placebo-mRNA-1273 BŽC`AA€Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Éê]¿=H?Ji|ÚÔtôB‡BùAB£Cp<$25,000Haber Milton (b)(6) (b)(6) USATexas Laredo 78041 2344 Laguna Del Mar Court, Suite 104 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US357 Placebo B6C`B*AàVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ãŽ8ãŽ8à?}:ªˆB3B.AABtC<$25,000Haber Milton (b)(6) (b)(6) USATexas Laredo 78041 2344 Laguna Del Mar Court, Suite 104 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US337 Placebo BCpAÀAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBAA°B6<$25,000Baron Mira V(b)(6) (b)(6) (b)(6) USAFlorida West Palm Beach 33409 2277 Palm Beach Lakes Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US337 mRNA-1273 BØCpApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BØBÙABGC+à<$25,000Baron Mira V(b)(6) (b)(6) (b)(6) USAFlorida West Palm Beach 33409 2277 Palm Beach Lakes Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US337 Placebo-mRNA-1273 BÉCpA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?·g*¤Lh?;¿þch°BÀC`AÀBDC,°<$25,000Baron Mira V(b)(6) (b)(6) (b)(6) USAFlorida West Palm Beach 33409 2277 Palm Beach Lakes Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US313 mRNA-1273 BOB¦A0AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BOBHA€B$B–<$25,000Doust Matthew W(b)(6) (b)(6) (b)(6) USAArizona Phoenix 85018 3900 E. Camelback Road, Suite 190 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US313 Placebo-mRNA-1273 B9B¦Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @÷}Áp?Š•µ[æíHB5B2A@B$B‚<$25,000Doust Matthew W(b)(6) (b)(6) (b)(6) USAArizona Phoenix 85018 3900 E. Camelback Road, Suite 190 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US313 Placebo BB¦BVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @qÇqÇ@ö„½¡/hBAÐA BB1<$25,000Doust Matthew W(b)(6) (b)(6) (b)(6) USAArizona Phoenix 85018 3900 E. Camelback Road, Suite 190 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US365 Placebo A B=AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A A A B<$25,000Marks Kristen M(b)(6) (b)(6) (b)(6) USANew York New York 10065 525 East 68th Street, Baker 24 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US365 Placebo-mRNA-1273 BB=AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BB—BB\<$25,000Marks Kristen M(b)(6) (b)(6) (b)(6) USANew York New York 10065 525 East 68th Street, Baker 24 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US365 mRNA-1273 BB=A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBlAAÐBj<$25,000Marks Kristen M(b)(6) (b)(6) (b)(6) USANew York New York 10065 525 East 68th Street, Baker 24 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US370 Placebo A B9AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A A@AP<$25,000Marks Kristen M(b)(6) (b)(6) (b)(6) USANew York New York 10010 53 West 23rd Street, 6th floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US370 mRNA-1273 BB9A AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BB>AA A°Bf<$25,000Marks Kristen M(b)(6) (b)(6) (b)(6) USANew York New York 10010 53 West 23rd Street, 6th floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US370 Placebo-mRNA-1273 BB9Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?º.‹¢èº0?µæµQGâÐBB™AAàB.<$25,000Marks Kristen M(b)(6) (b)(6) (b)(6) USANew York New York 10010 53 West 23rd Street, 6th floor mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US358 Placebo BBÄBVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBApAà<$25,000Jackson Lisa A(b)(6) (b)(6) (b)(6) USAWashington Seattle 98101 1730 Minor Avenue, Suite 1370 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US358 mRNA-1273 B^BÄA0A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?+“W& ®?+W‘ÙñãØB]B BBb<$25,000Jackson Lisa A(b)(6) (b)(6) (b)(6) USAWashington Seattle 98101 1730 Minor Avenue, Suite 1370 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US358 Placebo-mRNA-1273 BLBÄAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?5å yC^P?5‰ûc+üBKB„ABBF<$25,000Jackson Lisa A(b)(6) (b)(6) (b)(6) USAWashington Seattle 98101 1730 Minor Avenue, Suite 1370 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US385 mRNA-1273 BbBÇAPAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?)ËÁN^ r?)•HUnBaB£A B,BÒ<$25,000Allen III Leland N(b)(6) (b)(6) USAAlabama Birmingham 35205 800 St Vincent's Dr, North Tower, Suite 510 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US385 Placebo BBÇBA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @§¹a{–?À¼ðpæÈBBB"B<$25,000Allen III Leland N(b)(6) (b)(6) USAAlabama Birmingham 35205 800 St Vincent's Dr, North Tower, Suite 510 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US385 Placebo-mRNA-1273 BCBÇVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @"cWánÎT?ª¤z«pÈB:BpABBb<$25,000Allen III Leland N(b)(6) (b)(6) USAAlabama Birmingham 35205 800 St Vincent's Dr, North Tower, Suite 510 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US372 Placebo BC`AðA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BAAàB$<$25,000De La Cruz Luis I(b)(6) (b)(6) (b)(6) USASouth Carolina Greenville 29615 2 Roper Corners Circle mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US372 mRNA-1273 B×C`A@A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ? 0Ñ?¾Í BÖBgA0BMC`<$25,000De La Cruz Luis I(b)(6) (b)(6) (b)(6) USASouth Carolina Greenville 29615 2 Roper Corners Circle mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US372 Placebo-mRNA-1273 BÅC`AA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @–½¹ÓÑ8?[ê|þ#D B¯BfApB\C<$25,000De La Cruz Luis I(b)(6) (b)(6) (b)(6) USASouth Carolina Greenville 29615 2 Roper Corners Circle mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US343 mRNA-1273 CÀC( A@A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event >Ïdt¨žÈ>ÏaÏôÀÐC°C A°BICð<$25,000Baden Lindsey (b)(6) (b)(6) (b)(6) USAMassachusetts Boston 2115 75 Francis Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US343 Placebo BC( BA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?„!B„ ?úþ½VþøBBA AB)Be<$25,000Baden Lindsey (b)(6) (b)(6) (b)(6) USAMassachusetts Boston 2115 75 Francis Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US343 Placebo-mRNA-1273 CÐC( AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?žZ¹ áx?.¼Ä]^C C`A€BTC<$25,000Baden Lindsey (b)(6) (b)(6) (b)(6) USAMassachusetts Boston 2115 75 Francis Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US301 Placebo BC@BA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBBB=<$25,000Chu Laurence (b)(6) (b)(6) (b)(6) USATexas Austin 78705 3100 Red River Street, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US301 mRNA-1273 B™C@ApAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B™B¹A€BLCP<$25,000Chu Laurence (b)(6) (b)(6) (b)(6) USATexas Austin 78705 3100 Red River Street, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US301 Placebo-mRNA-1273 B€C@A0A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ? ?F$ˆÀv†˜B{BÆA@BSCÀ<$25,000Chu Laurence (b)(6) (b)(6) (b)(6) USATexas Austin 78705 3100 Red River Street, Suite 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US303 mRNA-1273 B C A€A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B BtA0B/Bœ<$25,000Vrbicky Keith W(b)(6) (b)(6) (b)(6) USANebraska Norfolk 68701 1410 N. 13th Street, Suite 5 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US303 Placebo-mRNA-1273 B…C A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @Ì³ìÀ?sŠrŠ®˜BuB•A€B-B<$25,000Vrbicky Keith W(b)(6) (b)(6) (b)(6) USANebraska Norfolk 68701 1410 N. 13th Street, Suite 5 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US303 Placebo BC BA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ @H/†ÄCBA°A AAÀB)<$25,000Vrbicky Keith W(b)(6) (b)(6) (b)(6) USANebraska Norfolk 68701 1410 N. 13th Street, Suite 5 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US399 Placebo A@B~A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A@A0Að<$25,000Mullane Kathleen M(b)(6) (b)(6) (b)(6) USAIllinois Chicago 60637 5841 S. Maryland Ave. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US399 mRNA-1273 B@B~AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B@B:BB®<$25,000Mullane Kathleen M(b)(6) (b)(6) (b)(6) USAIllinois Chicago 60637 5841 S. Maryland Ave. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US399 Placebo-mRNA-1273 B:B~Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @§¹a|?–óä[TI¨B5BPAB)B½<$25,000Mullane Kathleen M(b)(6) (b)(6) (b)(6) USAIllinois Chicago 60637 5841 S. Maryland Ave. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US374 Placebo BCBA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BB)APB<$25,000Kotloff Karen L(b)(6) (b)(6) USAMaryland Baltimore 21201 685 West Baltimore Street, HSF 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US374 mRNA-1273 BÞCA A`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?$æ¡qNj?ùž’E •BÜCA€B#Bq<$25,000Kotloff Karen L(b)(6) (b)(6) USAMaryland Baltimore 21201 685 West Baltimore Street, HSF 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US374 Placebo-mRNA-1273 B¾CAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¬v‘„ Çh?;m&«U2B¶C0ABB§<$25,000Kotloff Karen L(b)(6) (b)(6) USAMaryland Baltimore 21201 685 West Baltimore Street, HSF 1 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US376 Placebo ApCàApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ApApAPAÀ<$25,000Sanders John W(b)(6) (b)(6) (b)(6) USANorth Carolina Winston-Salem 27157 Peacock Infectious Disease Clinical Trials Center (ID-CTC), 1 Medical Center Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US376 mRNA-1273 BCàAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBBBB‘<$25,000Sanders John W(b)(6) (b)(6) (b)(6) USANorth Carolina Winston-Salem 27157 Peacock Infectious Disease Clinical Trials Center (ID-CTC), 1 Medical Center Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US376 Placebo-mRNA-1273 BˆCàVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ZZZZZZ\?3–43.°JB…B”ABB×<$25,000Sanders John W(b)(6) (b)(6) (b)(6) USANorth Carolina Winston-Salem 27157 Peacock Infectious Disease Clinical Trials Center (ID-CTC), 1 Medical Center Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US336 Placebo BCBAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBBB<$25,000Whatley Jordan L(b)(6) (b)(6) (b)(6) USALouisiana Baton Rouge 70809 7912 Summa Avenue mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US336 mRNA-1273 BšCA0APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BšBáBB9B¾<$25,000Whatley Jordan L(b)(6) (b)(6) (b)(6) USALouisiana Baton Rouge 70809 7912 Summa Avenue mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US336 Placebo-mRNA-1273 B†CA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @‘1«ð·g?r¼°râÃ1$BmB˜A@B!C <$25,000Martin Judith M(b)(6) (b)(6) (b)(6) USAPennsylvania Pittsburgh 15213 120 Lytton Avenue, Suite 100B mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US398 mRNA-1273 BƒC0A°A`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BƒBƒA°B,CP<$25,000White Judith (b)(6) (b)(6) USAFlorida Orlando 32806 100 West Gore Street, Suite 102 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US398 Placebo-mRNA-1273 BaC0APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Tt«‹àT?;OFáè¨B_BAÀB"Bþ<$25,000White Judith (b)(6) (b)(6) USAFlorida Orlando 32806 100 West Gore Street, Suite 102 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US398 Placebo BC0BA`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?„!B„ ?úþ½VþøBBA@BBe<$25,000White Judith (b)(6) (b)(6) USAFlorida Orlando 32806 100 West Gore Street, Suite 102 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US325 mRNA-1273 C°C,AÀA°Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event >¼ÝS]±ÌX>¼—›–QðC B–A B¶C1`<$25,000Solis Joel (b)(6) (b)(6) (b)(6) USATexas McAllen 78504 1020 Zinnia Ave mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US325 Placebo BNC,B>A`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?4ƒH4ƒH4?4,ÔE#BMBB>BÞ<$25,000Solis Joel (b)(6) (b)(6) (b)(6) USATexas McAllen 78504 1020 Zinnia Ave mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US325 Placebo-mRNA-1273 CðC,A AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¦B :‘x?1ÑpäC@B‰ApB|C*<$25,000Solis Joel (b)(6) (b)(6) (b)(6) USATexas McAllen 78504 1020 Zinnia Ave mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US377 Placebo BCÀBA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BAÐA AÐB?<$25,000Saleh Jamshid (b)(6) (b)(6) (b)(6) USACalifornia Redding 96001 3652 Eureka Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US377 mRNA-1273 B„CÀApAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?>ƒàø>?+Œ¼Í‘´B‚B^A BSC@<$25,000Saleh Jamshid (b)(6) (b)(6) (b)(6) USACalifornia Redding 96001 3652 Eureka Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US377 Placebo-mRNA-1273 BwCÀAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @Ð¬Ð¬?q:”É'¬BkBšA0BwC<$25,000Saleh Jamshid (b)(6) (b)(6) (b)(6) USACalifornia Redding 96001 3652 Eureka Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US333 mRNA-1273 B2BhAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B2BEApABG<$25,000Peterson James T(b)(6) (b)(6) USAUtah Salt Lake City 84109 2295 Foothill Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US333 Placebo-mRNA-1273 B%BhVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÝgÈ¦ Ö€?˜Dg®Ü«ðB#B5AAÐBX<$25,000Peterson James T(b)(6) (b)(6) USAUtah Salt Lake City 84109 2295 Foothill Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US333 Placebo AÀBhAÀAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @UUUUUU@lÔ+€A°AàAPA<$25,000Peterson James T(b)(6) (b)(6) USAUtah Salt Lake City 84109 2295 Foothill Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US397 Placebo A0BàA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A0AAA <$25,000Newberg Joseph L(b)(6) (b)(6) (b)(6) USAIllinois Chicago 60602 33 North Dearborn, Suite 500 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US397 mRNA-1273 BdBàA@A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BdBUA°A B0C@<$25,000Newberg Joseph L(b)(6) (b)(6) (b)(6) USAIllinois Chicago 60602 33 North Dearborn, Suite 500 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US397 Placebo-mRNA-1273 B^BàVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?‚¹1rb?JBR>¾MìB[BEA B$B©<$25,000Newberg Joseph L(b)(6) (b)(6) (b)(6) USAIllinois Chicago 60602 33 North Dearborn, Suite 500 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US356 mRNA-1273 BuBñA€A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BuBÝAPBB’<$25,000Davis Joseph D(b)(6) (b)(6) (b)(6) USAArizona Chandler 85224 600 S. Dobson Road, Building A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US356 Placebo-mRNA-1273 BgBñA AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Ÿeç%H?MùnMç€¸BcBËA BB”<$25,000Davis Joseph D(b)(6) (b)(6) (b)(6) USAArizona Chandler 85224 600 S. Dobson Road, Building A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US356 Placebo BBñBA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @0@úàÁZÓŠAÐBBB<$25,000Davis Joseph D(b)(6) (b)(6) (b)(6) USAArizona Chandler 85224 600 S. Dobson Road, Building A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US368 Placebo A0BÍA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A0AA<$25,000Clark Jesse L(b)(6) (b)(6) USACalifornia Los Angeles 90038 910 Vine Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US368 mRNA-1273 BaBÍAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BaB°ApBB/<$25,000Clark Jesse L(b)(6) (b)(6) USACalifornia Los Angeles 90038 910 Vine Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US368 Placebo-mRNA-1273 B^BÍAA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @W& ®LA?gEÉdA÷8BXBûAB(B!<$25,000Clark Jesse L(b)(6) (b)(6) USACalifornia Los Angeles 90038 910 Vine Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US316 mRNA-1273 B–C@A@AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ˆˆˆˆˆˆˆ?<„óyB2B‘C@A0B7BB<$25,000Kirstein Judith L(b)(6) (b)(6) (b)(6) USACalifornia Banning 92220 264 North Highland Springs Avenue, Suite 5A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US316 Placebo AðC@AÐAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @@|ë^7¢»AàBB*A<$25,000Kirstein Judith L(b)(6) (b)(6) (b)(6) USACalifornia Banning 92220 264 North Highland Springs Avenue, Suite 5A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US316 Placebo-mRNA-1273 BˆC@AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @!áááááâ?w¾}ÙBPBvC`AB=B]<$25,000Kirstein Judith L(b)(6) (b)(6) (b)(6) USACalifornia Banning 92220 264 North Highland Springs Avenue, Suite 5A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US324 Placebo AÐC0AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AÐAPA Ap<$25,000Finley Jon (b)(6) (b)(6) (b)(6) USAGeorgia Stockbridge 30281 175 Country Club Drive, Building 100, Suite A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US324 mRNA-1273 BÉC0A0APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?`ËÇõÏš?SÍ€ÀÊBÈB{ABBQ<$25,000Finley Jon (b)(6) (b)(6) (b)(6) USAGeorgia Stockbridge 30281 175 Country Club Drive, Building 100, Suite A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US324 Placebo-mRNA-1273 B»C0A A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ððððððð?Fz:‚K0˜B°BŸA0ABB@<$25,000Finley Jon (b)(6) (b)(6) (b)(6) USAGeorgia Stockbridge 30281 175 Country Club Drive, Building 100, Suite A mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US335 mRNA-1273 C0C%°BBVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event C0B“A B”Cp<$25,000Schwartz Howard I(b)(6) (b)(6) (b)(6) USAFlorida Hollywood 33024 7261 Sheridan Street, Suite 210, 215, 310 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US335 Placebo-mRNA-1273 BÜC%°A A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?]EÑt]?)'Üü„JüB×BrABuCÐ<$25,000Schwartz Howard I(b)(6) (b)(6) (b)(6) USAFlorida Hollywood 33024 7261 Sheridan Street, Suite 210, 215, 310 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US335 Placebo BFC%°B A°Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?uPuPt?Q›<¯ÀìBDBB;Be<$25,000Schwartz Howard I(b)(6) (b)(6) (b)(6) USAFlorida Hollywood 33024 7261 Sheridan Street, Suite 210, 215, 310 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US386 Placebo B'CpB"A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B'BBBj<$25,000El Sahly Hana M(b)(6) (b)(6) (b)(6) USATexas Houston 77030 Departments of Molecular Virology and Microbiology, One Baylor Plaza, Room 221D; MS: BCM280 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US386 mRNA-1273 BˆCpA`APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BˆBýAPAB?Cà<$25,000El Sahly Hana M(b)(6) (b)(6) (b)(6) USATexas Houston 77030 Departments of Molecular Virology and Microbiology, One Baylor Plaza, Room 221D; MS: BCM280 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US386 Placebo-mRNA-1273 B`CpA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ªªªªªª¨?S‰aLO(B\BÇApB*C€<$25,000El Sahly Hana M(b)(6) (b)(6) (b)(6) USATexas Houston 77030 Departments of Molecular Virology and Microbiology, One Baylor Plaza, Room 221D; MS: BCM280 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US310 Placebo B%CB#A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B%AðBB9<$25,000Hachigian Greg (b)(6) (b)(6) (b)(6) USACalifornia Sacramento 95864 4345 Arden Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US310 mRNA-1273 BËCAàA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BËBØAPBaBå<$25,000Hachigian Greg (b)(6) (b)(6) (b)(6) USACalifornia Sacramento 95864 4345 Arden Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US310 Placebo-mRNA-1273 B¥CVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?|Áð| ?6©CFØ‡xB B¼A BdBè<$25,000Hachigian Greg (b)(6) (b)(6) (b)(6) USACalifornia Sacramento 95864 4345 Arden Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US383 Placebo A€CPApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A€A0AA`B$<$25,000Mohan Gowdhami (b)(6) (b)(6) (b)(6) USASouth Carolina Anderson 29621 1665 E. Greenville Street, Building 2 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US383 mRNA-1273 B‡CPA0A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?<®u’Êè?*–ÙÞ20*B…BrA0B9B“<$25,000Mohan Gowdhami (b)(6) (b)(6) (b)(6) USASouth Carolina Anderson 29621 1665 E. Greenville Street, Building 2 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US383 Placebo-mRNA-1273 B~CPAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Ã0Ã0À?MµuûrØBxBbApBDB[<$25,000Mohan Gowdhami (b)(6) (b)(6) (b)(6) USASouth Carolina Anderson 29621 1665 E. Greenville Street, Building 2 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US346 mRNA-1273 BÔCpAA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BÔBTA`B<C°<$25,000Lucksinger Gregg H(b)(6) (b)(6) (b)(6) USAOregon Medford 97504 3860 Crater Lake Avenue, Suite B mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US346 Placebo B4CpB0A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?NÄìNÄìP?Nœÿ"”B3ApBBP<$25,000Lucksinger Gregg H(b)(6) (b)(6) (b)(6) USAOregon Medford 97504 3860 Crater Lake Avenue, Suite B mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US346 Placebo-mRNA-1273 BžCpVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?›‹W~a7?>H‡~#hB˜B&AàB8C<$25,000Lucksinger Gregg H(b)(6) (b)(6) (b)(6) USAOregon Medford 97504 3860 Crater Lake Avenue, Suite B mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US330 mRNA-1273 BçC0AðA`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BçBjA AB:B†<$25,000Feldman Gregory J(b)(6) (b)(6) (b)(6) USASouth Carolina Spartanburg 29303 141 Harold Fleming Court mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US330 Placebo BC0BA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?—´%í {@?”Þ,Á?Å BApAABB<$25,000Feldman Gregory J(b)(6) (b)(6) (b)(6) USASouth Carolina Spartanburg 29303 141 Harold Fleming Court mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US330 Placebo-mRNA-1273 BÎC0AAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @eç%Hâ?GÓÄËÆÄBÀB€A0B\C <$25,000Feldman Gregory J(b)(6) (b)(6) (b)(6) USASouth Carolina Spartanburg 29303 141 Harold Fleming Court mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US347 Placebo AàB„AàAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AàBAA°<$25,000Frank Ian (b)(6) (b)(6) (b)(6) USAPennsylvania Philadelphia 19104 3535 Market Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US347 mRNA-1273 B>B„A A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?B„!B?A‡’[H€B=BSAABBR<$25,000Frank Ian (b)(6) (b)(6) (b)(6) USAPennsylvania Philadelphia 19104 3535 Market Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US347 Placebo-mRNA-1273 B2B„A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?õÂ\(õÀ?‰‘+¶»ðB/B^BBp<$25,000Frank Ian (b)(6) (b)(6) (b)(6) USAPennsylvania Philadelphia 19104 3535 Market Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US366 mRNA-1273 B]B¼AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B]CA0B!B^<$25,000Fichtenbaum Carl J(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45267-0405Infectious Diseases Research Unit (Holmes-UC), 200 Albert Sabin Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US366 Placebo-mRNA-1273 BVB¼AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?î#¸Žâ;ˆ?g[b™Ÿ@BQC°A@B$Bs<$25,000Fichtenbaum Carl J(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45267-0405Infectious Diseases Research Unit (Holmes-UC), 200 Albert Sabin Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US366 Placebo A`B¼APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @*ªªªªªª@&òü a&TAPBCA`A <$25,000Fichtenbaum Carl J(b)(6) (b)(6) (b)(6) USAOhio Cincinnati 45267-0405Infectious Diseases Research Unit (Holmes-UC), 200 Albert Sabin Way mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US340 mRNA-1273 BïCàA A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?#Xç]03?(»TBîBˆA`BQC<$25,000Eder Frank S(b)(6) (b)(6) (b)(6) USANew York Binghamton 13901 1290 Upper Front Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US340 Placebo BCàBA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?„!B„ ?úþ½VþøBAàA BB?<$25,000Eder Frank S(b)(6) (b)(6) (b)(6) USANew York Binghamton 13901 1290 Upper Front Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US340 Placebo-mRNA-1273 BÏCàAA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?Ù©nPbð??Ü'ïÛg2BÄBA BKBÀ<$25,000Eder Frank S(b)(6) (b)(6) (b)(6) USANew York Binghamton 13901 1290 Upper Front Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US353 Placebo A C`A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A BA0A`<$25,000Anderson Evan J(b)(6) (b)(6) (b)(6) USAGeorgia Atlanta 30322 Emory Children's Center-Vaccine Research Clinic (ECC-VRC), 2015 Uppergate Drive NE mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US353 mRNA-1273 B}C`A AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ? Ä›¥ãSø? ¢üvçÁ`B|BæAPBB¶<$25,000Anderson Evan J(b)(6) (b)(6) (b)(6) USAGeorgia Atlanta 30322 Emory Children's Center-Vaccine Research Clinic (ECC-VRC), 2015 Uppergate Drive NE mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US353 Placebo-mRNA-1273 BsC`A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?²BÈY ?MämÒÝXPBnB·A`BŽB…<$25,000Anderson Evan J(b)(6) (b)(6) (b)(6) USAGeorgia Atlanta 30322 Emory Children's Center-Vaccine Research Clinic (ECC-VRC), 2015 Uppergate Drive NE mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US304 mRNA-1273 B–CBLAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?N´èO?7*½ GB•B‹A B.BÖ<$25,000Ensz David J(b)(6) (b)(6) (b)(6) USAIowa Sioux City 51106 4802 Sunnybrook Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US304 Placebo-mRNA-1273 BzCA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @#¬ÉqO¼?€lì\¸BiB…A@B/BÅ<$25,000Ensz David J(b)(6) (b)(6) (b)(6) USAIowa Sioux City 51106 4802 Sunnybrook Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US304 Placebo BCBAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @1;±;²@ÉhÓ5`üBB(A BB<<$25,000Ensz David J(b)(6) (b)(6) (b)(6) USAIowa Sioux City 51106 4802 Sunnybrook Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US321 mRNA-1273 BÍCðA@A`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?OìþÀOì?'‘¶4BÉC0AB6Bâ<$25,000Miller Vicki (b)(6) (b)(6) (b)(6) USATexas Tomball 77375 13406 Medical Complex Dr, Suite 190 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US321 Placebo BCðBA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @?ºŠ@ssA0BB+BB!<$25,000Miller Vicki (b)(6) (b)(6) (b)(6) USATexas Tomball 77375 13406 Medical Complex Dr, Suite 190 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US321 Placebo-mRNA-1273 BCðAA@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @<«§6À_?R™2‡ÐB CÐA`BCBµ<$25,000Miller Vicki (b)(6) (b)(6) (b)(6) USATexas Tomball 77375 13406 Medical Complex Dr, Suite 190 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US319 mRNA-1273 C€C:BAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?÷}Áp>ÊÍ¶œ}˜C`CÀAC C9`<$25,000McGettigan John W(b)(6) (b)(6) (b)(6) USAArizona Tucson 85712 5390 E. Erickson Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US319 Placebo BSC:BMA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÅeÈ{_P?`Jˆy³úÈBOB&AB‡C€<$25,000McGettigan John W(b)(6) (b)(6) (b)(6) USAArizona Tucson 85712 5390 E. Erickson Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US319 Placebo-mRNA-1273 C0C:AA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÆºN©¿#0?-°®dÝôNCC[pA`CÐC<<$25,000McGettigan John W(b)(6) (b)(6) (b)(6) USAArizona Tucson 85712 5390 E. Erickson Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US326 Placebo BCpBA`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BA`BBG<$25,000Adams Atoya (b)(6) (b)(6) (b)(6) USANevada Las Vegas 89119 2110 East Flamingo Road, Suite 103 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US326 mRNA-1273 BˆCpAðApVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BˆBWA@BOC<$25,000Adams Atoya (b)(6) (b)(6) (b)(6) USANevada Las Vegas 89119 2110 East Flamingo Road, Suite 103 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US326 Placebo-mRNA-1273 BtCpAA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?°=ËÓà?MB¡Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @)JR”¥)J?¿SwpO7¸B4BeAPB3BK<$25,000Kelley Colleen (b)(6) (b)(6) USAGeorgia Atlanta 30303 80 Jesse Hill Jr Dr. S.E. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US382 Placebo AðC@AàA0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event AðAPB&B<$25,000Kennelly Christina (b)(6) (b)(6) USANorth Carolina Charlotte 28210 6060 Piedmont Row Drive South, Floors 8 & 10 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US382 mRNA-1273 BèC@A0APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BèB¿A€ABrC50<$25,000Kennelly Christina (b)(6) (b)(6) USANorth Carolina Charlotte 28210 6060 Piedmont Row Drive South, Floors 8 & 10 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US382 Placebo-mRNA-1273 BÕC@A A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?`&uÈ¶¯x?*}ó÷\ûlBÐBìA@BfC4<$25,000Kennelly Christina (b)(6) (b)(6) USANorth Carolina Charlotte 28210 6060 Piedmont Row Drive South, Floors 8 & 10 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US345 mRNA-1273 BÓCBAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ióÞH?]ÃªˆD[BÒBAB.C <$25,000Griffin Carl P(b)(6) (b)(6) (b)(6) USAOklahoma Oklahoma City 73112 3555 N.W 58th Street, Suite 800 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US345 Placebo B-CB!A0Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¶`¶`¸?}ÔðºœŒB+ABB¦<$25,000Griffin Carl P(b)(6) (b)(6) (b)(6) USAOklahoma Oklahoma City 73112 3555 N.W 58th Street, Suite 800 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US345 Placebo-mRNA-1273 B¥CA A@Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ø>ƒàø@?LÌ'ê‚B›BKBBC €<$25,000Griffin Carl P(b)(6) (b)(6) (b)(6) USAOklahoma Oklahoma City 73112 3555 N.W 58th Street, Suite 800 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US331 mRNA-1273 CC'àA€A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event CC@A ABBã<$25,000Fierro Carlos A(b)(6) (b)(6) (b)(6) USAKansas Lenexa 66219 16300 College Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US331 Placebo B+C'àBA`Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ÜGqÄw?Ÿ ãl>ØB(B+A@AàBw<$25,000Fierro Carlos A(b)(6) (b)(6) (b)(6) USAKansas Lenexa 66219 16300 College Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US331 Placebo-mRNA-1273 BíC'àA0A€Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @®üÂn-^?K›ì¥ú´BØCAðBCð<$25,000Fierro Carlos A(b)(6) (b)(6) (b)(6) USAKansas Lenexa 66219 16300 College Blvd. mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US308 Placebo BCàBA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BBAAB8B-<$25,000Williams Barton G(b)(6) (b)(6) USANorth Carolina Wilmington 28403 1221 Floral Parkway, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US308 mRNA-1273 BzCàA`A Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BzBA0BB·<$25,000Williams Barton G(b)(6) (b)(6) USANorth Carolina Wilmington 28403 1221 Floral Parkway, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US308 Placebo-mRNA-1273 BaCàVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¨è?WÀ¨?R±§²ØB]BšABBå<$25,000Williams Barton G(b)(6) (b)(6) USANorth Carolina Wilmington 28403 1221 Floral Parkway, Suite 101 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US342 mRNA-1273 B‘CpA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B‘BJA ABB9<$25,000Creech II Clarence B(b)(6) (b)(6) USATennessee Nashville 37232 1161 21st Ave South mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US342 Placebo BCpBVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?£× =p£Ø? ‡žVNâÀBA`A`B<$25,000Creech II Clarence B(b)(6) (b)(6) USATennessee Nashville 37232 1161 21st Ave South mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US342 Placebo-mRNA-1273 B|CpVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?¥)JR”¥(?H[žÇÛÈBwBUAB B]<$25,000Creech II Clarence B(b)(6) (b)(6) USATennessee Nashville 37232 1161 21st Ave South mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US322 mRNA-1273 C@C)BA€Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?H°üÖéà?Ò¼céƒ1C B²BABîCO<$25,000Rankin Bruce G(b)(6) (b)(6) (b)(6) USAFlorida DeLand 32720 860 Peachwood Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US322 Placebo BOC)B7AÐVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?3Ù* g²?3„ÖÞƒÓbBNB)A@BqC@<$25,000Rankin Bruce G(b)(6) (b)(6) (b)(6) USAFlorida DeLand 32720 860 Peachwood Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US322 Placebo-mRNA-1273 BóC)AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?e"Ãó[§€?(Æ’$"4BíB«A ABÑCD<$25,000Rankin Bruce G(b)(6) (b)(6) (b)(6) USAFlorida DeLand 32720 860 Peachwood Drive mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US360 Placebo A°BA°AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event A°A`AÀB<$25,000Balani Bindu A(b)(6) (b)(6) USANew Jersey Hackensack 07601 20 Prospect Avenue, Suite 810 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US360 mRNA-1273 BKBA AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event BKBZABBt<$25,000Balani Bindu A(b)(6) (b)(6) USANew Jersey Hackensack 07601 20 Prospect Avenue, Suite 810 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US360 Placebo-mRNA-1273 BBBA AVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ø>ƒàø@?xMÜ?ðB>B•AÀB\B†<$25,000Balani Bindu A(b)(6) (b)(6) USANew Jersey Hackensack 07601 20 Prospect Avenue, Suite 810 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US300 mRNA-1273 B³CðA APVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?-ÃîÖ†oŽ? .O0èB±B‡A B)Cà<$25,000Essink Brandon J(b)(6) (b)(6) (b)(6) USANebraska Omaha 68134 3319 North 107th Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US300 Placebo B%CðBA°Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?n³äSë@?m2LôWB$BA BB<$25,000Essink Brandon J(b)(6) (b)(6) (b)(6) USANebraska Omaha 68134 3319 North 107th Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US300 Placebo-mRNA-1273 BCðAA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @ø¼Òœ$P?\ƒ#’H@lB‚B†ABBB®<$25,000Essink Brandon J(b)(6) (b)(6) (b)(6) USANebraska Omaha 68134 3319 North 107th Street mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US327 mRNA-1273 B¶CÐAAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B¶C@A`B=C@<$25,000Brosz Adam B(b)(6) (b)(6) USANebraska Grand Island 68803 2444 W. Faidley Avenue mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US327 Placebo BCÐBAPVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @±;±;?Ö xf&¬ØBB2AÀABB8<$25,000Brosz Adam B(b)(6) (b)(6) USANebraska Grand Island 68803 2444 W. Faidley Avenue mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US327 Placebo-mRNA-1273 BšCÐVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @"èº.‹¢è?qEãøxB…BÿA€B=BÊ<$25,000Brosz Adam B(b)(6) (b)(6) USANebraska Grand Island 68803 2444 W. Faidley Avenue mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US379 mRNA-1273 B1BfA Vaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event B1B(A BB’<$25,000Burgher Abram H(b)(6) (b)(6) (b)(6) USAArizona Phoenix 85023 2525 W. Greenway Road, Suite 240 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US379 Placebo-mRNA-1273 B)BfAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event ?ÇÎ|àÇÐ?‰Ë[£‹à@B'B.A0A°Bl<$25,000Burgher Abram H(b)(6) (b)(6) (b)(6) USAArizona Phoenix 85023 2525 W. Greenway Road, Suite 240 mRNA-1273-P301A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA 1273 SARS CoV 2 Vaccine in Adults Aged 18 Years and Older AModernaTX Inc. DM!Y.E³€.US379 Placebo ABfApAVaccine Efficacy of mRNA-1273 to prevent the first occurrence of COVID-19 starting 14 days after the second injection of IP time to event @qÇqÇ@ÑSoÿwA€APA€B<$25,000Burgher Abram H(b)(6) (b)(6) (b)(6) USAArizona Phoenix 85023 2525 W. Greenway Road, Suite 240